Vimseltinib Solid-State Forms for Selective CSF-1R Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CSF-1R inhibitors face challenges such as off-target toxicity and increased plasma levels of CSF-1, limiting their effectiveness in treating tumors and conditions like tenosynovial giant cell tumor (TGCT) and macrophage-related disorders, while different solid-state forms of active pharmaceutical ingredients can offer improved properties for better bioavailability and manufacturing.
Innovation Solution
Development of novel solid-state forms, including solvated forms, of the kinase inhibitor vimseltinib, which are specifically designed to target CSF-1R, addressing the limitations of existing inhibitors and providing enhanced stability, solubility, and manufacturing reproducibility.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing CSF-1R inhibitors are used, then tumor growth inhibition is achieved, but off-target toxicity and increased plasma levels of CSF-1 occur
Solution Approach 1:
The patent develops novel solid-state forms (polymorphs, solvates, co-crystals) of vimseltinib to modify its physical and chemical properties. These parameter changes in the solid-state structure improve the drug's stability, solubility, and bioavailability while maintaining selective CSF-1R inhibition, thereby reducing off-target toxicity associated with existing inhibitors
2Reliability
If existing CSF-1R inhibitors are used, then tumor growth inhibition is achieved, but plasma levels of CSF-1 increase
Solution Approach 1:
The novel solid-state forms of vimseltinib exhibit improved dissolution profiles and bioavailability compared to existing inhibitors. This enhanced parameter optimization allows for more precise control of drug release and plasma concentration, achieving effective tumor growth inhibition while minimizing the compensatory increase in CSF-1 plasma levels
3Reliability
If different solid-state forms are developed, then bioavailability and stability are improved, but manufacturing complexity increases
Solution Approach 1:
The patent identifies and characterizes specific polymorphic forms, solvates, and co-crystals of vimseltinib with optimized parameters for bioavailability and stability. By selecting particular solid-state forms with favorable properties and developing standardized preparation methods, the patent balances the benefits of improved performance with manageable manufacturing complexity
4Reliability
If particle size is reduced, then dissolution rate and bioavailability are improved, but flowability and handling decrease
Solution Approach 1:
The novel solid-state forms of vimseltinib are designed with optimized particle size distributions that balance dissolution rate enhancement with adequate flowability. The specific crystal structures and morphologies of the polymorphs and co-crystals provide favorable surface properties that maintain good flow characteristics even at reduced particle sizes, enabling improved bioavailability without compromising manufacturing handling
Data Source
AI summary
Described herein, in part, are solid-state forms of the compound represented by Formula (I), pharmaceutical compositions comprising the solid-state forms, processes of making the solid-state forms and methods of using the solid-state forms